Lutetium 177 ( 177 Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide
therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic …

Objectives Checkpoint inhibitors (CPIs) for low-and intermediate-grade neuroendocrine
tumors (NETs) have been associated with limited efficacy; recent studies suggest CPIs may …

Background Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for
metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan …

Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive
cancers characterized by a high Ki‐67 index, rapid tumor growth and poor survival, and are …

With great interest, we recently read Strosberg et al.’s publication regarding the risk of bowel
obstruction in patients with mesenteric/peritoneal disease who receive peptide receptor …

Data regarding the utility of peptide receptor radionuclide therapy (PRRT) for the treatment
of functional pancreatic neuroendocrine tumors (panNETs) are scarce. We present a case …

Purpose Falls can occur in older cancer patients, but few studies have examined falls in an
age-unspecified group of patients with locally advanced esophageal cancer. Because these …

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine
neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results …

Background: G3 NETs are a recently recognized entity and although the treatment
recommendations largely follow those for grade 1 and 2 NETs, the outcomes of therapy are inferior. …

Background: Low-(G1) and intermediate-grade (G2) neuroendocrine tumors (NET) are
defined by lower mitotic rates and genetic mutations that rarely cause transformation to high-…